MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41416-025-03243-7

Медицинская библиотека · British journal of cancer · 2025

Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.

Kloots Iris S H, Slootbeek Peter H J, Tolmeijer Sofie H, van Wilpe Sandra, Smits Minke, van Helvert Sjoerd, Kroeze Leonie I, van Ipenburg Jolique A, Grünberg Katrien, Kets C Marleen, Ligtenberg Marjolijn J L, Nagarajah James, Fütterer Jurgen, van Dodewaard Joyce M, van Voorthuizen Theo, Terheggen Frederiek, Smilde Tineke J, Schalken Jack A, van Oort Inge M, Bloemendal Haiko J, Gerritsen Winald R, Mehra Niven, PROMPT collaboration network

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Precision oncology using genotype-matched treatments (GMT) offers potential to improve survival in metastatic castration-resistant prostate cancer (mCRPC).

PATIENT AND

METHODS

In the PROMPT study (NCT04746300), reflex tumour testing through next-generation sequencing was performed in treatment-naïve or first-line mCRPC patients. All patients received a molecular tumour board (MTB) recommendation for GMT based on predefined druggable targets (DT). The main objective was to identify clinicopathological variables associated with DT.

RESULTS

Analysis included 340 tissue samples from 307 patients, 51% of samples were newly biopsied. Valid results were generated in 84% (76% new, 92% archived; P < 0.01). DT were identified in 39% of the patients, with PI3K-AKT (26%) and Homologous Recombination (HR; 21%) pathways most frequently affected. Metastatic tissue, especially from mCRPC setting (P < 0.01), yielded higher GMT recommendations than primary tissue (P = 0.03). HR-associated genes were linked with shorter ADT-to-CRPC time (OR 3.77, 95%CI 1.62-10.32, P < 0.01). PI3K-AKT alterations were associated with metachronous metastatic disease (OR 0.48, 95%CI 0.26-0.89, P = 0.021) and longer time to CRPC (OR 0.47, 95%CI 0.25-0.87, P = 0.017). No distinct variables predicted DT genotypes.

CONCLUSION

Molecular tumour testing should preferably be done on metastatic mCRPC tissue. No combination of features could robustly identify druggable genotypes; therefore, reflex molecular characterisation should be routine for every mCRPC patient.

Для цитирования: Kloots Iris S H, Slootbeek Peter H J, Tolmeijer Sofie H, van Wilpe Sandra, Smits Minke, van Helvert Sjoerd, Kroeze Leonie I, van Ipenburg Jolique A, Grünberg Katrien, Kets C Marleen, Ligtenberg Marjolijn J L, Nagarajah James, Fütterer Jurgen, van Dodewaard Joyce M, van Voorthuizen Theo, Terheggen Frederiek, Smilde Tineke J, Schalken Jack A, van Oort Inge M, Bloemendal Haiko J, Gerritsen Winald R, Mehra Niven, PROMPT collaboration network. Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.. British journal of cancer. 2025. DOI: 10.1038/s41416-025-03243-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.